Comparative Pharmacology
Head-to-head clinical analysis: DYMISTA versus PEDIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYMISTA versus PEDIOTIC.
DYMISTA vs PEDIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist; fluticasone propionate is a corticosteroid with anti-inflammatory activity. The combination reduces nasal symptoms by blocking histamine receptors and inhibiting inflammatory mediators.
PEDIOTIC contains hydrocortisone, neomycin, and polymyxin B. Neomycin and polymyxin B are antibiotics that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
One spray (137 mcg azelastine hydrochloride/50 mcg fluticasone propionate) per nostril twice daily, intranasal.
Instill 4 drops into the affected ear(s) twice daily for 7-10 days.
None Documented
None Documented
Azelastine: terminal half-life ~22 hours (plasma) with long-lasting antihistamine effect. Fluticasone propionate: terminal half-life ~7.8 hours (intravenous), but intranasal systemic exposure is very low.
Not established for topical otic use; systemic absorption is minimal. If absorbed, terminal half-life of dexamethasone is approximately 3-4 hours.
Azelastine: ~75% renal (primarily as parent and metabolites), ~25% fecal. Fluticasone propionate: <5% renal, >95% fecal as parent and metabolites.
Renal elimination of absorbed drug (primarily unchanged) accounts for <10% of topically applied dose; fecal/biliary routes negligible.
Category C
Category C
Antihistamine/Corticosteroid Combination
Otic Antibiotic/Corticosteroid Combination